FDA Approves Branched Aortic Arch Stent

How Does the New Aortic Arch Stent Work?

The aortic arch is the curved segment of the body’s largest artery, where major branches carry blood toward the brain and arms. That anatomy makes endovascular treatment especially difficult: a conventional covered stent can seal an aneurysm or dissection but may also obstruct essential branch vessels. A branched stent-graft is designed with additional channels or openings that preserve this circulation while excluding the damaged section from blood pressure.

Unlike traditional open repair, endovascular treatment is delivered through blood vessels using catheters and imaging guidance. It can reduce the need for a large chest incision and prolonged interruption of blood flow, but it is still major cardiovascular treatment. Some patients may require additional procedures to reposition or connect branch vessels before the graft can be implanted.

Who Could Benefit From Endovascular Aortic Arch Repair?

Potential candidates include people with certain aortic arch aneurysms, dissections or other lesions covered by the device’s FDA-approved labeling. Eligibility depends on detailed CT angiography, the location and extent of disease, vessel diameter, available areas for anchoring the graft and the relationship between the lesion and arteries supplying the brain.

The 2022 ACC/AHA aortic disease guideline emphasizes multidisciplinary evaluation and shared decision-making for complex aortic conditions. Cardiovascular surgeons, vascular surgeons, interventional specialists, radiologists and anesthesiologists may all contribute to treatment planning. Open surgery can remain the more durable or appropriate option for some patients, particularly when anatomy is unsuitable for a stent-graft.

What Risks Remain After FDA Approval?

Operating near arteries that supply the brain creates an important risk of stroke from interrupted circulation or dislodged material. Other recognized complications of thoracic endovascular aortic repair include endoleak, graft movement, access-vessel injury, spinal cord ischemia, kidney injury related to contrast material, infection and conversion to open surgery.

FDA approval indicates that regulators found sufficient evidence of safety and effectiveness for the device’s specified use; it does not mean the procedure is risk-free or appropriate for every form of aortic disease. Long-term imaging remains necessary because the aorta can change over time and device-related problems may develop after the initial repair. Outcomes will also depend on specialist training, careful patient selection and surveillance after implantation.